BLUE BELL, Pa.--(BUSINESS WIRE)--VGX Pharmaceuticals, Inc. (VGX) announced today that the U.S. Food and Drug Administration (FDA) has approved the Company’s Investigational New Drug (IND) application for its DNA vaccine for cervical cancer therapy, VGX-3100. The Company expects to initiate the Phase I clinical study for VGX-3100 in patients in a multi-center study in the third quarter of 2008. More information on this study is available at http://www.clinicaltrials.gov/ct2/show/NCT00685412?term=vgx&rank=1
